Stock market announcement archive

May 7, 2024
Lifecare AS will present Q1 2024 financial and operational status in a webcast Wednesday 8 May. The webcast will be for all shareholders and interested parties at 11:00 – 11:45 CET. Lifecare’s CEO Joacim Holter presents the company’s Q1 report followed by a Q&A session where Holter will answer questions submitted in advance. Questions in […]
Read more
May 2, 2024
Lifecare AS will hold an Extraordinary General Meeting on May 16th, 2024, at 10:00 (CET). The notice with complete agenda and documents are available on https://lifecare.no/events/. It will be possible to attend the meeting in person or digitally through Orgbrain. Shareholders who wish to participate and vote at the Extraordinary General Meeting must be registered with […]
Read more
April 30, 2024
The Annual General Meeting of Lifecare AS was convened as a hybrid meeting on 30 April 2024. Trine Teigland (Board member) and Lutz Heinemann (Board member) were re-elected and Tone Kvåle (Board member) was elected as new member of the BoD as proposed by the Nomination Committee. No alternative candidates were proposed. All proposals on […]
Read more
April 29, 2024
Bergen, Norway, 29 April 2024: Lifecare AS (LIFE), a clinical stage medical sensor company developing the next generation Continuous Glucose Monitor (CGM), have invested NOK 2 million through a private placement in RemovAid AS, a medical technology company based in Oslo, Norway, after which Lifecare holds 81.1% of the shares in RemovAid. RemovAid has developed […]
Read more
April 26, 2024
Bergen, Norway 26 April 2024: Hannibal Invest AS, a company closely associated with Hans Hekland, member of the Board of Directors of LifeCare AS (the “Company”), has on 26 April 2024 sold 150,000 shares in the Company at an average price of NOK 3.05 per share. Following this transaction, Hannibal Invest AS holds 50,000 shares […]
Read more
April 26, 2024
Bergen, Norway, 26th April 2024: Lifecare AS (LIFE), a clinical stage medical sensor company developing the next generation Continuous Glucose Monitor (CGM), intend to invest NOK 2 million and become the majority shareholder in RemovAid AS, a medical technology company based in Oslo, Norway. RemovAid is an ISO 13485 certified company who specializes in the […]
Read more
April 26, 2024
Correted item: Date of extraordinary meeting now consistently stated as 16 May 2024 NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA, THE HONG KONG SPECIAL ADMINISTRATIVE REGION OF THE PEOPLE’S REPUBLIC OF CHINA, JAPAN OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. […]
Read more
April 26, 2024
Bergen, Norway, 26 April 2024: Lifecare AS (LIFE), a clinical stage medical sensor company developing the next generation Continuous Glucose Monitor (CGM), intent to invite its existing shareholders in a NOK 90 million partially underwritten rights issue. The proposed rights issue will ensure preferential subscription rights for existing shareholders, with already underwritten guarantees a minimum […]
Read more
April 25, 2024
NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA, THE HONG KONG SPECIAL ADMINISTRATIVE REGION OF THE PEOPLE’S REPUBLIC OF CHINA, JAPAN OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. OTHER RESTRICTIONS ARE APPLICABLE. Reference is made to the stock exchange announcement published […]
Read more
April 25, 2024
NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA, THE HONG KONG SPECIAL ADMINISTRATIVE REGION OF THE PEOPLE’S REPUBLIC OF CHINA, JAPAN OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. OTHER RESTRICTIONS ARE APPLICABLE. PLEASE SEE THE IMPORTANT NOTICE AT THE END OF […]
Read more